Limits...
Cancer patients participating in a lifestyle intervention during chemotherapy greatly over-report their physical activity level: a validation study.

Vassbakk-Brovold K, Kersten C, Fegran L, Mjåland O, Mjåland S, Seiler S, Berntsen S - BMC Sports Sci Med Rehabil (2016)

Bottom Line: From SWA, Moderate-to-Vigorous intensity PA (MVPA) in bouts ≥10 min was compared with self-reported MVPA from the IPAQ-sf.Mean difference and limit of agreement between the IPAQ-sf and SWA including walking was 662 (±1719) min(.)wk(-1).When analyzing time spent in the different intensity levels separately, IPAQ-sf reported significantly higher levels of moderate (602 min(.)wk(-1), p = 0.001) and vigorous (60 min(.)wk(-1), p = 0.001) PA compared to SWA.

View Article: PubMed Central - PubMed

Affiliation: Oncologic Department, Southern Hospital Trust, Postbox 416, 4604 Kristiansand, Norway ; Department of Health and Sport Science, University of Agder, Postbox 422, 4604 Kristiansand, Norway.

ABSTRACT

Background: The short form of the International Physical Activity Questionnaire (IPAQ-sf) is a validated questionnaire used to assess physical activity (PA) in healthy adults and commonly used in both apparently healthy adults and cancer patients. However, the IPAQ-sf has not been previously validated in cancer patients undergoing oncologic treatment. The objective of the present study was to compare IPAQ-sf with objective measures of physical activity (PA) in cancer patients undergoing chemotherapy.

Methods: The present study was part of a 12-month prospective individualized lifestyle intervention focusing on diet, PA, stress management and smoking cessation in 100 cancer patients undergoing chemotherapy. During the first two months of the lifestyle intervention, participants were wearing an activity monitor (SenseWear™ Armband (SWA)) for five consecutive days while receiving chemotherapy before completing the IPAQ-sf. From SWA, Moderate-to-Vigorous intensity PA (MVPA) in bouts ≥10 min was compared with self-reported MVPA from the IPAQ-sf. Analyses both included and excluded walking in MVPA from the IPAQ-sf. Results were extrapolated to a wearing time of seven days.

Results: Sixty-six patients completed IPAQ-sf and wore the SWA over five days. Mean difference and limit of agreement between the IPAQ-sf and SWA including walking was 662 (±1719) min(.)wk(-1). When analyzing time spent in the different intensity levels separately, IPAQ-sf reported significantly higher levels of moderate (602 min(.)wk(-1), p = 0.001) and vigorous (60 min(.)wk(-1), p = 0.001) PA compared to SWA.

Conclusions: Cancer patients participating in a lifestyle intervention during chemotherapy reported 366 % higher MVPA level from the past seven days using IPAQ-sf compared to objective measures. The IPAQ-sf appears insufficient when assessing PA level in cancer patients undergoing oncologic treatment. Activity monitors or other objective tools should alternatively be considered, when assessing PA in this population.

No MeSH data available.


Related in: MedlinePlus

Bland-Altman plots depicting the mean differences (IPAQ-sf minus SenseWear Armband) for minutes spent in a Moderate-to-Vigorous intensity Physical Activity (MVPA) including walking, b MVPA excluding walking, c Moderate intensity PA (MPA) including walking and d MPA excluding walking. The solid line represents the mean, and the dashed lines represent the 1.96 SDs of the observations
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4837555&req=5

Fig1: Bland-Altman plots depicting the mean differences (IPAQ-sf minus SenseWear Armband) for minutes spent in a Moderate-to-Vigorous intensity Physical Activity (MVPA) including walking, b MVPA excluding walking, c Moderate intensity PA (MPA) including walking and d MPA excluding walking. The solid line represents the mean, and the dashed lines represent the 1.96 SDs of the observations

Mentions: The mean differences and limits of agreements between the IPAQ-sf and SWA from the Bland-Altman plots for time in MVPA were 662 (1719) min.wk−1 and 203 (1070) min.wk−1 with walking included and excluded in the analyses, respectively (Fig. 1a and b). Figure 1c and d depicts the mean differences and limits of agreements between the IPAQ-sf and the SWA from the Bland-Altman plots for time in MPA with walking included and excluded from the analyses; 602 (1694) min.wk−1 and 143 (1009) min.wk−1, respectively. Furthermore, Fig. 1 shows that several of the participants also under-reported their PA compared to the SWA (plots under the solid line). From the IPAQ-sf, 23 participants reported VPA during the last week. The SWA only identified three participants conducting VPA during the same seven-day period, and VPA is thus not depicted in a Bland-Altman plot. Linear regression revealed no significant systematic over-reporting; indicating those who had the highest levels of PA did not significantly over-report their PA levels the most. When comparing the min.wk−1 differences between IPAQ-sf and the MVPA recorded with SWA, analyses revealed a 366 % higher MVPA level reported on the IPAQ-sf compared to SWA (p = 0.001) (Table 2). After excluding walking from the analysis, the IPAQ-sf still reported statistically significant higher levels of MVPA; 112 % higher compared to the SWA (p = 0.007). When time in the different intensity categories were analyzed separately, IPAQ-sf reported significantly more time spent in MPA (602 min.wk−1, p = 0.001) and VPA (60 min.wk−1, p = 0.001) compared to SWA; 342 % and 1200 % more, respectively. Stratified analyses on mean differences between patients undergoing curative vs. palliative chemotherapy revealed no significant difference between the groups in over-report of MVPA (733 (443, 1023) vs. 521 (211, 832) min.wk−1, respectively, p = 0.395).Fig. 1


Cancer patients participating in a lifestyle intervention during chemotherapy greatly over-report their physical activity level: a validation study.

Vassbakk-Brovold K, Kersten C, Fegran L, Mjåland O, Mjåland S, Seiler S, Berntsen S - BMC Sports Sci Med Rehabil (2016)

Bland-Altman plots depicting the mean differences (IPAQ-sf minus SenseWear Armband) for minutes spent in a Moderate-to-Vigorous intensity Physical Activity (MVPA) including walking, b MVPA excluding walking, c Moderate intensity PA (MPA) including walking and d MPA excluding walking. The solid line represents the mean, and the dashed lines represent the 1.96 SDs of the observations
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4837555&req=5

Fig1: Bland-Altman plots depicting the mean differences (IPAQ-sf minus SenseWear Armband) for minutes spent in a Moderate-to-Vigorous intensity Physical Activity (MVPA) including walking, b MVPA excluding walking, c Moderate intensity PA (MPA) including walking and d MPA excluding walking. The solid line represents the mean, and the dashed lines represent the 1.96 SDs of the observations
Mentions: The mean differences and limits of agreements between the IPAQ-sf and SWA from the Bland-Altman plots for time in MVPA were 662 (1719) min.wk−1 and 203 (1070) min.wk−1 with walking included and excluded in the analyses, respectively (Fig. 1a and b). Figure 1c and d depicts the mean differences and limits of agreements between the IPAQ-sf and the SWA from the Bland-Altman plots for time in MPA with walking included and excluded from the analyses; 602 (1694) min.wk−1 and 143 (1009) min.wk−1, respectively. Furthermore, Fig. 1 shows that several of the participants also under-reported their PA compared to the SWA (plots under the solid line). From the IPAQ-sf, 23 participants reported VPA during the last week. The SWA only identified three participants conducting VPA during the same seven-day period, and VPA is thus not depicted in a Bland-Altman plot. Linear regression revealed no significant systematic over-reporting; indicating those who had the highest levels of PA did not significantly over-report their PA levels the most. When comparing the min.wk−1 differences between IPAQ-sf and the MVPA recorded with SWA, analyses revealed a 366 % higher MVPA level reported on the IPAQ-sf compared to SWA (p = 0.001) (Table 2). After excluding walking from the analysis, the IPAQ-sf still reported statistically significant higher levels of MVPA; 112 % higher compared to the SWA (p = 0.007). When time in the different intensity categories were analyzed separately, IPAQ-sf reported significantly more time spent in MPA (602 min.wk−1, p = 0.001) and VPA (60 min.wk−1, p = 0.001) compared to SWA; 342 % and 1200 % more, respectively. Stratified analyses on mean differences between patients undergoing curative vs. palliative chemotherapy revealed no significant difference between the groups in over-report of MVPA (733 (443, 1023) vs. 521 (211, 832) min.wk−1, respectively, p = 0.395).Fig. 1

Bottom Line: From SWA, Moderate-to-Vigorous intensity PA (MVPA) in bouts ≥10 min was compared with self-reported MVPA from the IPAQ-sf.Mean difference and limit of agreement between the IPAQ-sf and SWA including walking was 662 (±1719) min(.)wk(-1).When analyzing time spent in the different intensity levels separately, IPAQ-sf reported significantly higher levels of moderate (602 min(.)wk(-1), p = 0.001) and vigorous (60 min(.)wk(-1), p = 0.001) PA compared to SWA.

View Article: PubMed Central - PubMed

Affiliation: Oncologic Department, Southern Hospital Trust, Postbox 416, 4604 Kristiansand, Norway ; Department of Health and Sport Science, University of Agder, Postbox 422, 4604 Kristiansand, Norway.

ABSTRACT

Background: The short form of the International Physical Activity Questionnaire (IPAQ-sf) is a validated questionnaire used to assess physical activity (PA) in healthy adults and commonly used in both apparently healthy adults and cancer patients. However, the IPAQ-sf has not been previously validated in cancer patients undergoing oncologic treatment. The objective of the present study was to compare IPAQ-sf with objective measures of physical activity (PA) in cancer patients undergoing chemotherapy.

Methods: The present study was part of a 12-month prospective individualized lifestyle intervention focusing on diet, PA, stress management and smoking cessation in 100 cancer patients undergoing chemotherapy. During the first two months of the lifestyle intervention, participants were wearing an activity monitor (SenseWear™ Armband (SWA)) for five consecutive days while receiving chemotherapy before completing the IPAQ-sf. From SWA, Moderate-to-Vigorous intensity PA (MVPA) in bouts ≥10 min was compared with self-reported MVPA from the IPAQ-sf. Analyses both included and excluded walking in MVPA from the IPAQ-sf. Results were extrapolated to a wearing time of seven days.

Results: Sixty-six patients completed IPAQ-sf and wore the SWA over five days. Mean difference and limit of agreement between the IPAQ-sf and SWA including walking was 662 (±1719) min(.)wk(-1). When analyzing time spent in the different intensity levels separately, IPAQ-sf reported significantly higher levels of moderate (602 min(.)wk(-1), p = 0.001) and vigorous (60 min(.)wk(-1), p = 0.001) PA compared to SWA.

Conclusions: Cancer patients participating in a lifestyle intervention during chemotherapy reported 366 % higher MVPA level from the past seven days using IPAQ-sf compared to objective measures. The IPAQ-sf appears insufficient when assessing PA level in cancer patients undergoing oncologic treatment. Activity monitors or other objective tools should alternatively be considered, when assessing PA in this population.

No MeSH data available.


Related in: MedlinePlus